Overall survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in survival rates at 3 years compared with chemotherapy alone (low certainty).
1 finding from 1 review
Survival rates at 5 years · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · patients with extensive SCLC without previous treatment
1 finding from 1 review
Adverse effects · patients with extensive SCLC without previous treatment
1 finding from 1 review
Overall survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower overall survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
12‐month survival rates · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower 12‐month survival rates compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower progression‐free survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Tumor response rate · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to higher tumor response rate compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Toxicity – anemia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet showed no clear difference in toxicity – anemia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – neutropenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – neutropenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – thrombocytopenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – thrombocytopenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Progression‐free survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival: all participants compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival in people with central nervous system disease · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in overall adverse events compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Overall survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower overall survival compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review